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Abstract Autoimmune bullous skin diseases are
characterized by autoantibodies and T cells speciWc to
structural proteins maintaining cell–cell and cell–
matrix adhesion in the skin. Existing clinical and exper-
imental evidence generally supports a pathogenic role
of autoantibodies for blister formation. These autoan-
tibodies belong to several IgG subclasses, which associ-
ate with diVerent functional properties and may thus
determine the pathogenic potential of IgG antibodies.
In pemphigus diseases, binding of IgG to keratinocytes
is suYcient to cause intraepidermal blisters without
engaging innate immune eVectors and IgG4 autoanti-
bodies seem to mainly mediate acantholysis. In con-
trast, in most subepidermal autoimmune blistering
diseases, complement activation and recruitment and
activation of leukocytes by autoantibodies are required
for blister induction. In these conditions, tissue damage
is thought to be mainly mediated by IgG1, but not
IgG4 autoantibodies. This review summarizes the cur-
rent knowledge on the pathogenic relevance of the IgG
subclass of autoantibodies for blister formation. Char-
acterization of the pathogenically relevant subclass(es)
of autoantibodies not only provides mechanistic
insights, but should greatly facilitate the development
of improved therapeutic modalities of autoimmune
blistering diseases.
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Introduction
Autoimmune blistering diseases are associated with an
autoimmune response directed to structural proteins
mediating cell–cell and cell–matrix adhesion in the skin
[62, 66]. Both autoantibodies and autoreactive T cells
have been found in patients with these organ-speciWc
autoimmune diseases. However, blister induction is
mainly mediated by autoantibodies. Autoimmune blis-
tering diseases are classiWed based on the ultrastruc-
tural site of deposition of immunoreactants and on the
molecular target of autoantibodies. Diseases of the
pemphigus group are associated with autoantibodies to
epidermal components mediating cell–cell adhesion
and are characterized by acantholytic blisters within
the epidermis [39,  71]. Tissue-bound and circulating
autoantibodies to the dermal–epidermal junction are
characteristic immunopathological features of subepi-
dermal autoimmune bullous diseases [62, 85]. Target
antigens of autoantibodies have been identiWed for the
majority of autoimmune blistering diseases. In most of
these diseases, the pathogenicity of autoantibodies is
supported by clinical observations and extensive exper-
imental evidence [62].
Antibodies are eVector molecules of the adaptive
immune system secreted by plasmablasts and long-
lived plasma cells. Antibody responses are physiologi-
cally mounted following an infection or vaccination
and protect against various pathogens. Occasionally, in
the setting of an autoimmune disease, antibodies to
autologous structures may develop and cause diVerent
forms of tissue damage. The immunopathology
induced by autoantibodies, similar to the immunity
mediated by antibodies to pathogens, relies on several
mechanisms of action of antibodies, including direct
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mechanisms, which are mediated by the antibody’s var-
iable regions (e.g., by steric hindrance and signal trans-
duction), and indirect mechanisms, which are triggered
by the constant regions of antibodies. For the latter,
(auto)antibodies typically interact through their Fc
portions with other factors of the innate immune sys-
tem, including the complement system and inXamma-
tory cells [62].
Antibodies of the IgG isotype predominate in the
systemic immune response, as reXected in serum
immunoglobulin concentration, and activate a wide
range of eVector functions. Four subclasses of IgG are
deWned, originally from the antigenic uniqueness of
their heavy chains, which are products of distinct genes
[20,  27,  77]. The subclasses are designated as IgG1,
IgG2, IgG3 and IgG4 in order of their serum concen-
tration »60, 25, 10 and 5%, respectively. Although the
heavy chains show >95% sequence homology, each
IgG subclass expresses a unique proWle of eVector
activities [35, 56, 59, 76, 80, 82]. Protein antigens char-
acteristically provoke IgG1 and IgG3 responses and
these isotypes are able to activate all types of Fc recep-
tors and the C1 component of complement. The IgG4
subclass may be characteristic of chronic antigen stimu-
lation, as in autoimmune disease; it has restricted Fc
receptor activating abilities and does not activate C1q.
The IgG2 subclass often predominates in responses to
carbohydrate antigens; it has restricted Fc receptor and
C1 activating abilities [35, 56, 80, 82].
The pathogenic potential unfolded by autoantibod-
ies is determined not only by their speciWcity and aYn-
ity, but also by their isotype. Autoantibodies against
cutaneous proteins in autoimmune blistering diseases
belong to diVerent IgG subclasses. This paper summa-
rizes the current knowledge on the relevance of IgG
subclasses for tissue injury in autoimmune bullous dis-
eases.
Pemphigus diseases
Pemphigus designates a group of life-threatening-auto-
immune blistering diseases characterized by intraepi-
thelial blister formation caused by loss of cell–cell
adhesion [39,  54, 71]. IgG autoantibodies in patients
with pemphigus seem to mediate their pathogenic
functions independently of their Fc portions [62].
Patients’ IgG autoantibodies are pathogenic in C5-deW-
cient mice and F(ab’)2, Fab, and scFv fragments of
autoantibodies induce acantholysis by passive transfer
in wild type mice showing that complement activation
or other Fc-mediated eVects are not required for path-
ogenicity [4, 21, 45, 55].
Numerous studies clearly demonstrated that tissue
bound and circulating autoantibodies in pemphigus
p a t i e n t s  m a i n l y  b e l o n g  t o  t h e  I g G 1  a n d  I g G 4  s u b -
classes [2, 5, 8, 9, 16–18, 23, 28, 36, 38, 40, 49, 61, 79].
The IgG subclass distribution of autoantibodies in a
representative pemphigus patient is shown in Fig. 1.
While it is generally agreed upon the subclass distribu-
tion of IgG autoantibodies, the relevance of autoanti-
bodies of diVerent IgG isotypes for acantholytic
blistering in pemphigus is still a matter of debate. IgG4
autoantibodies, known to have poor complement- and
leucocyte-activating properties, predominate in pem-
phigus vulgaris and foliaceus. While several studies
suggest a pathogenic role of IgG4 in pemphigus, the
capacity of IgG1 autoantibodies to induce acantholysis
has not yet been ruled out. In patients with active pem-
phigus vulgaris, IgG4 autoantibodies against desmogle-
ins were found to predominate [5,  17,  23,  40]. The
transplacental transfer of these autoantibodies in
mothers with pemphigus induces acantholytic skin dis-
ease in neonates [52]. In endemic pemphigus foliaceus
the early antibody response in normal subjects living in
the endemic area and in patients before the onset of
clinical disease is mainly IgG1. Acquisition of an IgG4
response seems to be a key step in the development of
clinical disease [78]. Clinical and experimental data
suggests that IgG1 diVer from IgG4 autoantibodies in
terms of both their epitope speciWcity and pathogenic
potential [9, 42]. A monoclonal IgG4 antibody against
desmoglein 3 generated from a patient with active
pemphigus vulgaris induces acantholysis in cultured
skin and when injected in neonatal mice [86]. The fact
that IgG4 antibodies puriWed from patients with fogo
selvagem, an endemic form of pemphigus foliaceus, are
pathogenic in mice further supports the notion that
IgG4 is pathogenic and complement activation is not
required for blister formation [57], but does not
exclude a pathogenic potential of IgG autoantibodies
belonging to other subclasses. Indeed, in several pem-
phigus foliaceus patients, only IgG1 autoantibodies
were found that caused intraepidermal blisters by pas-
sive transfer into neonatal mice [29]. This observation
clearly shows that autoantibodies of diVerent sub-
classes may display blister-inducing activity. In addi-
tion, in paraneoplastic pemphigus, autoantibodies
against desmoglein 3 mainly belong to the IgG1 and
IgG2 subclasses suggesting that the IgG subclass per se
is not a direct determinant of the antibodies’ patho-
genic potential in pemphigus [24].
Experimental evidence using a murine model of
pemphigus vulgaris shows that, similar to human pem-
phigus, the autoimmune response in mice is biased
toward non-complement Wxing autoantibodies. In thisArch Dermatol Res (2007) 299:1–8 3
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model, in immunodeWcient mice infused with spleno-
cytes from desmoglein-deWcient mice immunized
against this antigen, IgG autoantibodies are produced
by homeostatically expanded antigen-speciWc B cells
under T cell control and mice develop a phenotype
reminiscent of pemphigus vulgaris. These IgG autoan-
tibodies predominantly belong to the IgG1 subclass,
which is a non-complement Wxing antibody in the
mouse [3,  50]. These results demonstrate that non-
complement-Wxing autoantibodies can induce acan-
tholysis and suggest a similar mechanism in patients,
but they do not exclude a pathogenic potential of
patients’ IgG1 autoantibodies in pemphigus.
In conclusion, in pemphigus diseases the autoanti-
bodies mainly belong to the IgG4 and IgG1 subclasses.
Extensive experimental evidence demonstrates the
blister-inducing potential of IgG4 autoantibodies. The
pathogenic activity of autoantibodies of other sub-
classes seems likely, but needs further investigation.
Subepidermal autoimmune blistering diseases
Bullous pemphigoid and pemphigoid gestationis
Bullous pemphigoid is an autoimmune blistering dis-
ease characterized by subepidermal blisters and associ-
ated with linear deposits of C3 and IgG at the
epidermal basement membrane zone. Autoantibodies
in bullous pemphigoid are directed against two
hemidesmosomal antigens, BP230 and BP180/type
XVII collagen [87]. Pemphigoid gestationis, also
referred to as herpes gestationis, is a subepidermal blis-
tering disease associated with pregnancy and character-
ized by linear deposition of C3 and, to a lesser extent of
IgG at the dermal–epidermal junction, as detected by
immunoXuorescence microscopy [62, 66]. The autoim-
mune response in bullous pemphigoid and pemphigoid
gestationis is mainly directed against epitopes clustered
within the immunodominant 16th non-collagenous
(NC16) A region of type XVII collagen [48, 65, 88].
Experimental evidence generally supports the path-
ogenic role of autoantibodies against type XVII colla-
gen for blister formation. Data from passive transfer
animal models strongly suggest that antibodies to type
XVII collagen are directly involved in the pathogenesis
of bullous pemphigoid [44,  84]. In addition, in an
ex vivo model utilizing cryosections of human skin, it
has been demonstrated that binding of autoantibodies
to the immunodominant NC16A domain of type XVII
collagen, is the Wrst critical step in subepidermal blister
formation [31, 64].
Analysis of the subclass distribution of IgG autoan-
tibodies in the skin of patients with bullous pemphigoid
by immunoXuorescence microscopy, revealed IgG4 as
being the predominant subclass of autoantibodies in
bullous pemphigoid, followed by IgG1 autoantibodies,
while IgG2 and IgG3 autoantibodies were found only
occasionally [1, 10–12, 22, 61, 83]. In addition, serum
autoantibodies binding to the dermal–epidermal junc-
tion by immunoXuorescence microscopy also mainly
belong to the IgG4 and IgG1 subclasses [10, 11, 61, 83].
Fig. 1 IgG subclass distribu-
tion of circulating pemphigus 
autoantibodies. A 1:10 dilu-
tion of serum from a patient 
with pemphigus foliaceus was 
incubated with 6 m-thick 
cryostat sections of normal 
human skin for 30 min at 
room temperature. Bound 
antibodies, visualized using an 
FITC-labeled antibody spe-
ciWc to human IgG, were of a 
IgG1 and d IgG4 subclasses. 
In contrast, no binding of b 
IgG2 and c IgG3 autoantibod-
ies was evidenced4 Arch Dermatol Res (2007) 299:1–8
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Subsequent molecular analysis of IgG autoantibodies
by immunoblotting and ELISA generally conWrmed
the predominance of IgG1 and IgG4 autoantibodies
reactive with type XVII collagen and BP230 (Fig. 2) [6,
19, 32, 41, 69].
In contrast to bullous pemphigoid, in pemphigoid
gestationis tissue-bound and circulating autoantibodies
seem to mainly belong to the IgG1 and IgG3 subclasses
[14,  37]. However, a recent study challenged these
reports revealing IgG4 as the predominant IgG sub-
class of tissue-bound autoantibodies in pemphigoid
gestationis patients [53], a pattern similar to the one
found in bullous pemphigoid. Further studies should
solve this contradiction.
Data from several studies in patients suggested a
pathogenic role of IgG1 autoantibodies for blister for-
mation (brieXy reviewed in [43]). In a recent study,
ELISA analysis showed that autoantibodies against the
N-terminus of the extracellular domain of type XVII
collagen predominantly belong to the IgG1 subclass.
More importantly, a NC16A-speciWc IgG1 response
was predominant in the acute phase of bullous pem-
phigoid, while IgG4 was predominantly detected in
bullous pemphigoid patients in remission [32]. Using
immunoaYnity puriWed IgG subclasses, it has been
shown that IgG1, but not IgG4 autoantibodies from
bullous pemphigoid patients activate the complement
system in vitro (Fig. 3) [46, 72]. This observation is in
line with the currently accepted view that IgG4 is
unable to activate the classical pathway of comple-
ment. However, until recently it was unclear which IgG
subclass is actually pathogenic in bullous pemphigoid.
Using the ex vivo cryosection model, we demonstrated
that, in addition to IgG1, IgG4 autoantibodies are also
able to activate leukocytes and to induce leukocyte-
dependent tissue damage (Fig. 4) [46]. Our results are
in line with recent studies demonstrating that both
polyclonal human IgG1 and IgG4 from patients with
Wegener’s granulomatosis and chronic urticaria can
activate leukocytes [33, 70]. Although the pathogenic
potential of IgG4 autoantibodies was signiWcantly
lower compared to IgG1, IgG4 autoantibodies, which
generally predominate, may activate the inXammatory
cells already recruited into the upper dermis by com-
plement-Wxing IgG1 autoantibodies and thus amplify
the recruitment of additional leukocytes and the extent
of blister formation. Therefore, when associated with
IgG1 and/or IgG3 autoantibodies, IgG4 may signiW-
cantly contribute to the pathology induced by autoanti-
bodies in antibody-induced granulocyte-mediated
autoimmune blistering diseases [46].
Several reports suggested that binding of bullous
pemphigoid antibodies to keratinocytes triggers a sig-
nal transduction [58,  73–75]. Bullous pemphigoid
autoantibodies trigger a signal-transducing event that
Fig. 2 IgG1 and IgG4 autoantibodies mainly target type XVII
collagen in bullous pemphigoid. Immunoblot analysis of serum
from a bullous pemphigoid patient with recombinant type XVII
collagen revealed that reactivity against its immunodominant do-
main consists mainly of IgG1 (lane 1) and IgG4 (lane 4), and less
IgG2 (lane 2) and IgG3 (lane 3) autoantibodies
Fig. 3 IgG4 autoantibodies, in contrast to IgG1, do not Wx com-
plement to the dermal–epidermal junction in bullous pemphig-
oid. Cryosections of normal human skin were incubated with
serum and immunoaYnity puriWed IgG1 and IgG4 antibody prep-
arations from a bullous pemphigoid patient and, subsequently,
treated with normal human serum as a source of complement.
Both a serum and b puriWed IgG1 autoantibodies Wxed comple-
ment C3 at the dermal–epidermal junction in a linear fashion. c In
contrast, incubation of cryosections with IgG4 speciWc for the der-
mal–epidermal junction does not result in C3 deposition (all mag-
niWcations, £200)Arch Dermatol Res (2007) 299:1–8 5
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leads to expression and secretion of interleukin-6 and
interleukin-8 from human cultured keratinocytes [58].
A series of studies from another group demonstrated
that IgG1 autoantibodies from bullous pemphigoid
patients and rabbit IgG against type XVII collagen
induces Ca2+ release from intracellular storage sites
[73–75]. Interestingly, complement activation by these
IgG1 autoantibodies did not result in lysis of keratino-
cytes [73]. While the relevance of these Wndings is not
yet fully understood, IgG2 and IgG4 patients’ autoanti-
bodies were found to inhibit the transient increase of
intracellular Ca2+ induced by bullous pemphigoid IgG1
antibody [74].
Mucous membrane pemphigoid
Mucous membrane pemphigoid is a heterogeneous dis-
ease with regard to the clinical phenotype and the tar-
get antigens. DiVerent target antigens have been
identiWed in mucous membrane pemphigoid, including
BP180, laminins 5 (epiligrin) and 6, 4 integrin [62, 66].
In general, autoantibodies in mucous membrane pem-
phigoid mainly belong to the IgG4 and IgG1 subclasses
[7, 34]. Interestingly, in anti-epiligrin cicatricial pem-
phigoid, autoantibodies against laminin 5 almost exclu-
sively belong to the IgG4 subclass [34]. Consistent with
these Wndings, sera from patients with anti-laminin 5
IgG autoantibodies do not Wx C3 to the epidermal
basement membranes and do not induce leukocyte-
dependent dermal–epidermal separation in vitro [34,
60]. These data suggest that complement activation
does not play a major role in this disease and subepi-
dermal blisters in these patients may develop via a
direct eVect of anti-laminin 5 IgG itself [34, 60].
Diseases associated with autoimmunity against type 
VII collagen
Epidermolysis bullosa acquisita is a chronic subepider-
mal blistering disease characterized by circulating and
tissue-bound antibodies targeting the non-collagenous
domain 1 (NC1) of type VII collagen. The pathogenic
relevance of antibodies against type VII collagen is
supported by compelling evidence: (1) autoantibodies
from patients with epidermolysis bullosa acquisita
were shown to recruit and activate leukocytes ex vivo
resulting in dermal–epidermal separation in cryosec-
tions of human skin [60, 63], (2) antibodies against type
VII collagen induce subepidermal blisters when pas-
sively transferred into mice [67, 81], (3) immunization
with recombinant autologous type VII collagen
induces an autoimmune response to this protein result-
ing in a blistering phenotype closely resembling human
epidermolysis bullosa acquisita [68].
Tissue-bound and circulating antibodies in epiderm-
olysis bullosa acquisita patients mainly belong to the
IgG1 and IgG4 subclasses [7, 15, 26, 47]. A similar dis-
tribution of IgG subclasses of autoantibodies is found
also in SJL mice immunized against murine type VII
collagen [68]. In these mice, while both non-comple-
ment-Wxing IgG1 and complement-Wxing IgG2a and
IgG2b autoantibodies are produced after immuniza-
tion, IgG2a/b autoantibodies seem to induce blistering
[68].
Systemic lupus erythematosus and inXammatory
bowel diseases may be also associated with autoanti-
bodies against type VII collagen [13, 25, 30, 51]. How-
ever, in contrast to epidermolysis bullosa acquisita,
autoantibodies from patients with bullous systemic
lupus erythematosus and inXammatory bowel diseases
mainly belong to IgG2 and IgG3, respectively [30, 51].
The pathogenic relevance of autoantibodies against
type VII collagen in inXammatory bowel diseases has
not yet been addressed [51]. IgG autoantibodies from
patients with bullous systemic lupus erythematosus
were shown to induce leukocyte-dependent dermal–
epidermal separation in cryosections of human skin
ex vivo [30]. This Wndings suggest that the presence of
complement-Wxing autoantibodies is not a strict
requirement for blistering in patients.
Fig. 4 IgG4 autoantibodies from bullous pemphigoid patients in-
duce dermal–epidermal separation in sections of human skin.
Dermal–epidermal separation in sections of normal human skin
is induced by a IgG1 and b IgG4 autoantibodies from a bullous
pemphigoid patient. c IgG antibodies from a healthy control
(NHS) do not induce subepidermal splits (all magniWcations,
£200)6 Arch Dermatol Res (2007) 299:1–8
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Conclusion and perspectives
The polyclonal antibody response against structural
skin proteins in autoimmune bullous diseases is hetero-
geneous, but shows a skewing in subclass distribution of
autoantibodies. The strong bias toward production of
IgG4 autoantibodies in these organ-speciWc autoim-
mune diseases suggests chronic antigenic stimulation. In
pemphigus, IgG4 autoantibodies that dominate the
autoimmune response are clearly pathogenic. However,
IgG1 autoantibodies also likely possess blister-inducing
potential that requires further investigation. In subepi-
dermal autoimmune blistering diseases, the eVector
functions of autoantibodies are important for blistering.
Thus, in bullous pemphigoid and epidermolysis bullosa
acquisita, complement-Wxing IgG1 autoantibodies may
show a signiWcantly higher pathogenic potential when
compared with IgG4 autoantibodies. Characterization
of the blister-inducing capacity of diVerent subclasses of
autoantibodies in autoimmune bullous diseases will not
only provide relevant mechanistic insights, but should
also greatly facilitate the development of improved
therapeutic modalities of autoimmune blistering dis-
eases. Detailed knowledge on the pathogenic IgG iso-
type(s) will serve as a basis for the development of IgG
subclass-speciWc immunoapheresis, skewing autoanti-
body production toward non-pathogenic subclasses by
immunotherapy or blocking of complement or leuko-
cytes activation by targeting speciWc IgG subclasses. A
promising approach is represented by interventions
aimed at inhibiting the production of autoantibodies in
general or skewing the production of autoantibodies
toward non-pathogenic subclasses. The molecular tar-
gets of these approaches may include diVerent cyto-
kines (e.g., IL-12 and IL-17) and their activity could be
modulated using inhibitory antibodies, small peptide
inhibitors or peptidomimetics as well as immunization
with the autoantigen together with adjuvants known to
induce a Th2 immune response.
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